Agilus Diagnostics has radically shortened the turnaround time (TAT) for myeloid malignancy genomic testing to just 3 days, significantly faster than the typical two-to-three-week wait at most labs. This accelerated process empowers physicians to make critical decisions sooner, offering timely interventions and potentially improved outcomes for patients with Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN).
The Myeloid Genomics Testing covers 79 genes, including those linked to inherited risks, detecting key mutations and fusions. Each report undergoes expert review by molecular pathologists, ensuring personalized treatment recommendations and risk assessment tools tailored to current standards.
“Our 3-day genomic testing initiative for myeloid malignancies addresses one of the biggest challenges in precision oncology - Time. With this breakthrough, Agilus Diagnostics is not only setting a new industry standard but also transforming patient care by enabling faster diagnoses and treatment,” said Dr. Anand K, Managing Director & CEO of Agilus Diagnostics.
Valued at around USD 150 million, India’s genomic testing market is growing at a CAGR of over 15%, driven by advancing technology and the need for personalized medicine. Agilus Diagnostics remains at the forefront by offering rapid, accurate, and comprehensive testing to streamline patient care and enhance therapeutic outcomes
Agilus Diagnostics, holds the largest network of NABL-accredited laboratories in India. This extensive network spans 25 states and five union territories, covering over 1,000 towns and cities and more than 532 districts. It includes one Global Reference Laboratory in Mumbai and five regional reference laboratories in Gurugram (Haryana), Bengaluru (Karnataka), Chennai (Tamil Nadu), Kolkata (West Bengal), and Cochin (Kerala).
